Cross-Sector entity

Biogen

Company BIIB
5.4

Of the tracked stories, 3 of 5 also mention Emily Felix, the most common co-covered peer. Across a 135-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 3. regulation accounts for 3 of the 5 tracked stories, while 2 other categories carry the remainder.

5 verified stories tracked

Last mentioned: Aug 4, 2026

RSS updates
Share

Entity pulse

Recent coverage · Biogen

↓
5 stories
5.4 avg impact
40% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 40 percentage points.

  • 40% positive
  • 60% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Biogen

Of the tracked stories, 3 of 5 also mention Emily Felix, the most common co-covered peer. Across a 135-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 3. regulation accounts for 3 of the 5 tracked stories, while 2 other categories carry the remainder. 0% of these stories carry negative sentiment. The tracked stories average 2.4 original sources each. Biogen appears in 5 tracked Cross-Sector stories published from March 23, 2026 through August 4, 2026.

Stories tracked
5
Per week
0.3
Negative
0%
Sources per story
2.4

Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Biogen. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Expected Deal Close

    The all-stock merger is anticipated to close, pending shareholder and regulatory approvals.

  2. Merger and Earnings Announcement

    Supernus unveils definitive agreement to merge with Indivior and releases Q2 2026 financial results.

  3. High Court grants permission for judicial review

    Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.

  4. Official Rollout

    Scotland officially begins screening all newborns for the rare muscle disease.

  5. Data Evaluation

    Expected first review of screening efficacy and treatment referral rates in Scotland.

  6. NCPE pharmacoeconomic evaluation completed

    The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.

  7. Scottish Policy Review

    Scottish health officials evaluate the feasibility of independent implementation.

  8. HSE reimbursement application filed

    Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.

  9. European market authorisation

    The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.

  10. Clinical Advocacy

    Intense campaigning by rare disease groups for the inclusion of SMA in UK-wide screening.

  11. Diagnosis with Friedreich's ataxia

    Emily Felix, then 12 years old, is diagnosed with the rare, progressive neuromuscular disease.

Stories mentioning Biogen 5

Healthcare acquisition Positive 6

Supernus–Indivior Merger Creates 11-Drug CNS Giant, $125M Synergy Target

Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.

4 sources

Source: The Motley Fool · Eric Volkman (us)

Healthcare regulation Positive 6

Scotland Breaks Ranks to Launch UK's First Newborn Screening for Muscle Disease

Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for a rare genetic muscle disease. This landmark policy shift aims to identify affected infants at birth, allowing for immediate intervention and treatment before the onset of irreversible physical symptoms.

2 sources

Source: lancashiretelegraph.co.uk · echo-news.co.uk